Effectiveness of Transition from Intravenous Epoprostenol to Oral/Inhaled Targeted Pulmonary Arterial Hypertension Therapy in Pediatric Idiopathic and Familial Pulmonary Arterial Hypertension
Authors:
- Robyn J. BarstRBRobyn J. Barst
- Cherise A. RowanCRCherise A. Rowan
- Diane KersteinDKDiane Kerstein
- Erika B. RosenzweigERErika B. Rosenzweig
- 1 May 2010
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 105 (10) , 1485-1489
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001–2006Heart, 2008
- Safety Experience With Bosentan in 146 Children 2–11 Years Old With Pulmonary Arterial Hypertension: Results from the European Postmarketing Surveillance ProgramPediatric Research, 2008
- Pulmonary arterial hypertension in children: a medical updateCurrent Opinion in Pediatrics, 2008
- Sildenafil Citrate Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2005
- Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled studyThe Journal of Heart and Lung Transplantation, 2001
- Vasodilator Therapy for Primary Pulmonary Hypertension in ChildrenCirculation, 1999
- Primary pulmonary hypertension in children: Clinical characterization and survivalJACC, 1995
- Primary Pulmonary HypertensionChest, 1993
- Survival in Patients with Primary Pulmonary HypertensionAnnals of Internal Medicine, 1991
- Primary Pulmonary HypertensionAnnals of Internal Medicine, 1987